Incidence, Timing, and Predictive Factors of New-Onset Migraine Headache Attack After Transcatheter Closure of Atrial Septal Defect or Patent Foramen Ovale

American Journal of Cardiology

Volumn 101, Issue 5, 2008, Pages 688-692

  Rodés Cabau, Josep ^a   Mineau, Sophie ^b   Marrero, Alier ^c   Houde, Christine ^c   Mackey, Ariane ^c   Côté, Jean Marc ^c   Chetaille, Philippe ^c   Delisle, George ^c   Bertrand, Olivier F ^a   Rivest, Donald ^d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d the Centre Hospitalier Universitaire de Québec ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; WARFARIN;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HEART ATRIUM SEPTUM DEFECT; HEART SURGERY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE AURA; MULTIVARIATE ANALYSIS; PATENT FORAMEN OVALE; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE; WOUND CLOSURE; AGE; BALLOON OCCLUSION; HEART SEPTUM DEFECT; HOSPITALIZATION; TIME;

ADULT; AGE FACTORS; BALLOON OCCLUSION; FEMALE; FOLLOW-UP STUDIES; FORAMEN OVALE, PATENT; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; INCIDENCE; MALE; MIGRAINE DISORDERS; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 41949127146     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.034     Document Type: Article

References (20)

1. Schwerzmann M., Nedeltchev K., and Meier B. Patent foramen ovale closure: a new therapy for migraine. Catheter Cardiovasc Interv 69 (2007) 277-284
2. Willmshurst P.T., Nightingale S., Walsh K.P., and Morrison W.L. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356 (2000) 1648-1651
3. Rodés-Cabau J., Molina C., Serrano-Munuera C., Casaldaliga J., Alvarez-Sabin J., Evangelista A., and Soler-Soler J. Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv 60 (2003) 540-542
4. Sharifi M., Dehghani M., Mehdipour M., Al-Bustami O., Emrani F., and Burks J. Intense migraines secondary to percutaneous closure of atrial septal defects. J Interv Cardiol 18 (2005) 181-183
5. Fernández-Mayoralas D.M., Fernández-Jaen A., Muñoz-Jareño N., Gutiérrez-Larraya F., Calleja-Pérez B., and San Antonio Arce V. Migraine symptoms related to the percutaneous closure of an ostium secundum atrial septal defect: report of four paediatric cases and review of the literature. Cephalalgia 27 (2007) 550-556
6. Mortelmans K., Post M., Thijs V., Herroelen L., and Budts W. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 26 (2005) 1533-1537
7. Headache classification committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 (1988) 196
8. Winner P., Wasiewski W., Gladstein J., and Linder S. Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria. Pediatric headache committee of the American Association for the Study of Headache. Headache 37 (1997) 545-548
9. Yew G., and Wilson N.J. Transcatheter atrial septal closure with the Amplatzer septal occluder: five-year follow-up. Catheter Cardiovasc Interv 64 (2005) 193-196
10. Slavin L., Tobis J.M., Rangarajan K., Dao C., Krivokapich J., and Liebeskind D.S. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol 99 (2007) 1316-1320
11. Wertman B., Azarbal B., Riedl M., and Tobis J. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 47 (2006) 1226-1227
12. Harms V., Reisman M., Fuller C.J., Spencer M.P., Olsen J.V., Krabill K.A., Gray W.A., and Jesurum J. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Am J Cardiol 99 (2007) 1312-1315
13. Wilmshurst P.T., Nightingale S., Walsh K.P., and Morrison W.L. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 91 (2005) 1173-1175
14. Ries M.W., Kampmann C., Rupprecht H.J., Hintereder G., Hafner G., and Meyer J. Nickel release after implantation of the Amplatzer occluder. Am Heart J 145 (2003) 737-741
15. Sharafuddin M.J.A., Gu X., Titus J.L., Urness M., Cervera-Ceballos J.J., and Amplatz K. Transvenous closure of secundum atrial septal defects. Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation 95 (1997) 2162-2168
16. Rodés-Cabau J., Palacios A., Palacio C., Girona J., Galve E., Evangelista A., Casaldaliga J., Albert D., Pico M., and Soler-Soler J. Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects. Int J Cardiol 98 (2005) 107-112
17. Bédard E., Rodés-Cabau J., Houde C., Mackey A., Rivest D., Cloutier S., Noel M., Marrero A., Cote J.M., Chetaille P., Delisle G., Leblanc M.H., and Bertrand O.F. Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. Stroke 38 (2007) 100-104
18. Yankosvsky A.E., and Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 43 (2003) 496-498
19. Gupta V.K. Closure of atrial septal defect and migraine. Headache 26 (2005) 1446
20. Kedhi E., and Vermeersch T.P. The influence of the percutaneous closure of atrial septal defect on the occurrence of migraine. Eur Heart J 26 (2005) 2746-2747